Acquisition expands research in cancer immunology
Boehringer Ingelheim acquires Abexxa to develop novel cancer therapies by leveraging Abexxa’s unique technology and breakthrough antibody-based drugs.
Search
Inauguration of new integrated Asian Veterinary R&D Center in China
Boehringer Ingelheim confirms its commitment to growth in China with the investment of 19 million euros in its new integrated Asian Veterinary Research & Development Center
Boehringer Ingelheim 2022 half year results
First half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline
2018 Animal Welfare Medals
2018 Animal Welfare Medals: Boehringer Ingelheim recognizes outstanding research in cattle, equine, swine, as well as small animals and pet categories
Four Pillars Cancer Immunology
Boehringer Ingelheim is focusing cancer immunology research on T cell engagers, cancer vaccines, oncolytic viruses and immune & stromal modulation
Boehringer Ingelheim collaborates with Circle Pharma
Boehringer Ingelheim collaborates with Circle Pharma to develop a first-in-class cyclin RxL inhibitor that can halt the growth of cancer cells
Central Nervous System Diseases
Find out more about our research and development in central nervous system diseases
collaboration-Yale
Yale-Boehringer Ingelheim Biomedical Data Science Fellowship Program Seeks to Attract Top Researchers from Around the World
Cardio-Renal-Metabolic Research
Read about our patient-centric approach to cardio-renal-metabolic disease research.
DCRI-collaboration-empact-mi
Collaboration with Duke Clinical Research Institute on EMPACT-MI trial, which will assess outcomes in people who have had a myocardial infarction
Research-collaboration-Gubra-obesity-treatment
Boehringer Ingelheim and Gubra enter collaboration to identify and validate targets and innovative peptides for the treatment of obesity.
PRRS Research Award 2022
Bridging science and veterinary practice for swine health: The winners of the European PRRS Award 2022
Retinal Health Research
Our research is targeting key mechanisms in the pathogenesis of retinal diseases – vascular dysfunction, neuronal dysfunction and neuronal inflammation.
Boehringer-Ingelheim's-half-year-figures-2021
Press release on Boehringer Ingelheim's half-year figures 2021. Business development from January to June 2021.
Partnering Vanderbilt WCNDD
Boehringer Ingelheim and the Warren Center for Neuroscience Drug Discovery are partnering to find new medicines for patients with neuropsychiatric disorders.
Disentangling fibrosis
Fibrosis is an important area of research for Boehringer Ingelheim that is focusing on fibrotic conditions of the liver, lung, kidney, skin and gut.
International Postdocs realize their potential in Biberach
Three talented postdocs report on what they are working at Boehringer Ingelheim's research site in Biberach and what attracts them to the company.
First Translational Medicine Award awarded
The Award recognizes the research that has the highest translational potential
Retinal Health: Meet the Scientists
We aim to prevent, treat, and restore vision loss. Delve behind the lab to see our scientists spearheading research to address retinopathies.
Behind the Lab
Delve behind the lab to see how our Retinal Health scientists are spearheading research into novel therapeutics to treat retinopathies.
Boehringer Ingelheim collaborates with the Broad Institute
Boehringer Ingelheim and researchers at the Broad Institute of MIT and Harvard are collaborating to tackle the unmet needs of people living with mental health conditions.
Quality
At Boehringer Ingelheim, Quality is deeply embedded into the lifecycle of the product: from Research and development to the delivery to our patients.
Our Partners_ViraTherapeutics
Lisa Egerer, COO and Patrik Erlman, Head of Research at ViraTherapeutics talk about their partnering journey with Boehringer Ingelheim.
2021 ABCD Young Scientist Award feline health
Young veterinary researchers Julia Klaus and Dr Yasmin Parr receive award for their work into feline SARS-CoV-2 infections and feline leukaemia virus.
“My ultimate goal is to cure cancer”
Norbert Kraut, our Global Head of Cancer Research, shares how we are advancing science to bring new treatment options for people living with cancer.